CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis. / Sellebjerg, F; Ross, C; Koch-Henriksen, Nils; Sørensen, P Soelberg; Frederiksen, J L; Bendtzen, K; Sørensen, Torben Lykke.

I: Multiple Sclerosis, Bind 11, Nr. 6, 01.12.2005, s. 641-5.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Sellebjerg, F, Ross, C, Koch-Henriksen, N, Sørensen, PS, Frederiksen, JL, Bendtzen, K & Sørensen, TL 2005, 'CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis', Multiple Sclerosis, bind 11, nr. 6, s. 641-5.

APA

Sellebjerg, F., Ross, C., Koch-Henriksen, N., Sørensen, P. S., Frederiksen, J. L., Bendtzen, K., & Sørensen, T. L. (2005). CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis. Multiple Sclerosis, 11(6), 641-5.

Vancouver

Sellebjerg F, Ross C, Koch-Henriksen N, Sørensen PS, Frederiksen JL, Bendtzen K o.a. CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis. Multiple Sclerosis. 2005 dec. 1;11(6):641-5.

Author

Sellebjerg, F ; Ross, C ; Koch-Henriksen, Nils ; Sørensen, P Soelberg ; Frederiksen, J L ; Bendtzen, K ; Sørensen, Torben Lykke. / CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis. I: Multiple Sclerosis. 2005 ; Bind 11, Nr. 6. s. 641-5.

Bibtex

@article{67d6e02e89434169a4d51325e9a12479,
title = "CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis",
abstract = "Biomarkers that allow the identification of patients with multiple sclerosis (MS) with an insufficient response to immunomodulatory treatment would be desirable, as currently available treatments are only incompletely efficacious. Previous studies have shown that the expression of CD25, CD26 and CCR5 on T cells is altered in patients with active MS. We studied the expression of these molecules by flow cytometry in patients followed for six months during immunomodulatory treatment. In interferon (IFN)-beta-treated patients, we found that the hazard ratio for developing an attack was 28 in patients with CD26 + CD4 + T cell counts above median, and this risk was independent of the risk conferred by neutralizing anti-IFN-beta antibodies. CD26 + CD4 + T cell counts may identify patients with MS at increased risk of attack during treatment with IFN-beta.",
author = "F Sellebjerg and C Ross and Nils Koch-Henriksen and S{\o}rensen, {P Soelberg} and Frederiksen, {J L} and K Bendtzen and S{\o}rensen, {Torben Lykke}",
year = "2005",
month = dec,
day = "1",
language = "English",
volume = "11",
pages = "641--5",
journal = "Multiple Sclerosis Journal",
issn = "1352-4585",
publisher = "SAGE Publications",
number = "6",

}

RIS

TY - JOUR

T1 - CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis

AU - Sellebjerg, F

AU - Ross, C

AU - Koch-Henriksen, Nils

AU - Sørensen, P Soelberg

AU - Frederiksen, J L

AU - Bendtzen, K

AU - Sørensen, Torben Lykke

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Biomarkers that allow the identification of patients with multiple sclerosis (MS) with an insufficient response to immunomodulatory treatment would be desirable, as currently available treatments are only incompletely efficacious. Previous studies have shown that the expression of CD25, CD26 and CCR5 on T cells is altered in patients with active MS. We studied the expression of these molecules by flow cytometry in patients followed for six months during immunomodulatory treatment. In interferon (IFN)-beta-treated patients, we found that the hazard ratio for developing an attack was 28 in patients with CD26 + CD4 + T cell counts above median, and this risk was independent of the risk conferred by neutralizing anti-IFN-beta antibodies. CD26 + CD4 + T cell counts may identify patients with MS at increased risk of attack during treatment with IFN-beta.

AB - Biomarkers that allow the identification of patients with multiple sclerosis (MS) with an insufficient response to immunomodulatory treatment would be desirable, as currently available treatments are only incompletely efficacious. Previous studies have shown that the expression of CD25, CD26 and CCR5 on T cells is altered in patients with active MS. We studied the expression of these molecules by flow cytometry in patients followed for six months during immunomodulatory treatment. In interferon (IFN)-beta-treated patients, we found that the hazard ratio for developing an attack was 28 in patients with CD26 + CD4 + T cell counts above median, and this risk was independent of the risk conferred by neutralizing anti-IFN-beta antibodies. CD26 + CD4 + T cell counts may identify patients with MS at increased risk of attack during treatment with IFN-beta.

M3 - Journal article

VL - 11

SP - 641

EP - 645

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

SN - 1352-4585

IS - 6

ER -

ID: 34092817